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CRISPR-Cas immune systems are present in around half of bacterial
genomes. Given the specificity and adaptability of this immune mechanism,
it is perhaps surprising that they are not more widespread. Recent insights
into the requirement for specific host factors for the function of some
CRISPR-Cas subtypes, as well as the negative epistasis between CRISPR-
Cas and other host genes, have shed light on potential reasons for the partial
distribution of this immune strategy in bacteria. In this study, we examined
how mutations in the bacterial mismatch repair system, which are frequently
observed in natural and clinical isolates and cause elevated host mutation
rates, influence the evolution of CRISPR-Cas–mediated immunity. We
found that hosts with a high mutation rate very rarely evolved CRISPR-
based immunity to phage compared to wild-type hosts. We explored the
reason for this effect and found that the higher frequency at which surface
mutants pre-exist in the mutator host background causes them to rapidly
become the dominant phenotype under phage infection. These findings
suggest that natural variation in bacterial mutation rates may, therefore,
influence the distribution of CRISPR-Cas adaptive immune systems.
This article is part of a discussion meeting issue ‘The ecology and
evolution of prokaryotic CRISPR-Cas adaptive immune systems’.1. Introduction
In the face of infection by bacteriophages (phage), bacteria have evolved a
range of molecular mechanisms that provide immunity [1–4]. Arguably, one
of their most sophisticated defences is CRISPR-Cas (Clustered Regularly Inter-
spaced Short Palindromic Repeats; CRISPR-associated), an adaptive immune
system. These immune systems are highly diverse and based on their cas
gene synteny and CRISPR repeat sequences; they are currently classified into
two classes, six types and 33 subtypes [5] that display clear differences in
their molecular mechanisms of action. Nonetheless, all variants confer the abil-
ity to acquire sequence-specific phage resistance through the insertion of short
pieces of phage-derived DNA (spacers) into CRISPR loci in the host genome
(reviewed in [6]). Upon re-infection, processed transcripts of CRISPR loci
(crRNA) guide CRISPR-associated (Cas) proteins to bind complementary
sequences in the phage genome, followed by endonucleolytic cleavage of the
phage DNA and/or RNA (depending on the CRISPR-Cas subtype) to clear
the infection (reviewed in [7]).
Despite the obvious benefits of CRISPR-mediated phage resistance when
phages are present in the environment [8], the majority of bacterial genomes
lack a CRISPR-Cas adaptive immune system [9–13], an estimate that undoubt-
edly is subject to sampling biases, as some clades of unculturable bacteria
appear to be essentially devoid of CRISPR systems [14]. This is in stark contrast
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2with restriction-modification defence systems, which are pre-
sent on average at two copies per cell [15] and raises the
question why the fraction of bacterial genomes that encode
CRISPR systems is so low. The common observation that
CRISPR-Cas systems frequently move between species by
horizontal gene transfer (HGT) suggests that the opportunity
to acquire these systems is at least not a limiting factor, and
instead suggests that these systems are frequently gained
and subsequently lost again [12,16–24]. Several mutually
non-exclusive explanations for this have been proposed.
First, it appears to be the case that CRISPR-Cas systems are
associated with autoimmunity issues due to self-targeting
that could drive the loss of these systems from bacterial gen-
omes [25–27]—a principle that is taken advantage of when
applying CRISPR-Cas systems as antimicrobials [28–32]. In
the context of lysogenization (i.e. when temperate phages
integrate into the host genome), similar effects may occur,
although at least some CRISPR-Cas variants appear to have
mechanisms to provide some protection against self-cleavage
in these instances [33,34]. An alternative explanation for the
absence of CRISPR-Cas systems from many genomes is that
they form a barrier for HGT. While this may in some cases
be protective, it can also prevent the acquisition of potentially
beneficial genetic information, and can, therefore, cause selec-
tion for bacteria with inactivated CRISPR-Cas systems when
HGT is an important fitness determinant [27,35–37]. Yet,
another explanation is that bacteria with CRISPR-Cas adaptive
immunity can be outcompeted by bacteria with alternative
defences under some ecological conditions [8,38–40]. Assum-
ing there is a fitness trade-off associated with encoding
CRISPR-Cas adaptive immune systems [41], then natural selec-
tion could favour loss of CRISPR-Cas systems in these
environments (reviewed in [37,42]).
While each of these factors is likely to contribute to the
overall phylogenetic distribution of CRISPR-Cas immune sys-
tems in bacteria, it is becoming increasingly clear that there are
additional constraints that arise from the host genetic context.
This is because the co-occurrence of certain non-cas genes is, in
some cases, a prerequisite for encoding a fully functional
CRISPR-Cas system, or because of epistatic interactions
between non-cas genes and CRISPR-Cas systems. For example,
during the first stage of the CRISPR-Cas immune response
when new spacers are captured and integrated into the
CRISPR array, the non-Cas protein, integration host factor
(IHF), has been shown to be crucial in type I–E and I–F sys-
tems [43,44]. IHF guides spacer integration to the correct
promoter-proximal end of the CRISPR array, where spacers
provide the highest levels of resistance to re-infection
[43–46]. Another example where an accessory host factor is
essential for CRISPR functioning is in type II systems, which
generally require RNase III for processing of the pre-CRISPR
RNA transcript into short CRISPR RNA molecules (crRNA)
that guide Cas complexes to target and destroy foreign
elements [47–49].
Apart from these examples where host factors are essen-
tial, there are also instances of both positive and negative
epistasis between CRISPR systems and other genes encoded
by the same host. For example, type II-ACRISPR-Cas systems
(specifically the Csn2 protein) inhibit the non-homologous
end joining (NHEJ) DNA repair pathway, and as a conse-
quence, these two systems almost never co-occur in the
same genome [50]. The opposite can also happen, where sys-
tems act synergistically. For example, interference levels ofEscherichia coli type I CRISPR-Cas systems depend on the
presence of a homologue of heat shock protein 90 (HtpG)
[51], the presence of a restriction-modification system has
been shown to enhance the performance of a type II
CRISPR-Cas immune system encoded by the same host
[52], and it was reported that RecBCD-mediated DNA degra-
dation products could feed into the spacer acquisition
machinery of a type I CRISPR-Cas system [53].
While these examples illustrate how the host genetic
context can determine whether or not acquisition of a
CRISPR-Cas immune system would likely provide a fitness
advantage, this list of examples is far from complete and our
understanding of the way host genetic context and CRISPR-
Cas interact is still rudimentary. Such knowledge is important
for understanding the observed distribution of these systems,
but also in an applied context, if we are to equip bacteria with
CRISPR-Cas immunity to protect them against phage preda-
tion, for example, to protect fermentation in industrial settings.
Here, we examine whether bacterial mutation rates may
form a barrier for the expression of the benefits associated
with CRISPR-Cas adaptive immune systems. Bacterial
mutation rates typically range from 1 in 10 million to 1 in a
billion base substitutions per nucleotide per generation
(reviewed in [54]), but bacteria with approximately 100-fold
higher mutation frequencies are frequently found in both
natural and clinical environments [55–57]. These high
mutation rates are often due to inactivated mismatch repair
systems and can either reduce or enhance bacterial fitness
depending on the environment [58–61]. It is tempting to
speculate that, in the context of phage predation, the benefits
of CRISPR-Cas may be reduced in a host genetic background
that has high mutation rates, because (i) these populations
generate beneficial surface resistance mutations at a much
higher frequency and (ii) high mutation rates may increase
the rate at which CRISPR immunity is lost through mutation
of cas genes or spacers in the CRISPR array [62].
To test these ideas, we performed experimental evolution
with Pseudomonas aeruginosa strain UCBPP-PA14, a clinical
isolate and model system for studying the evolution of
CRISPR resistance in response to its phage DMS3vir [8,63].
Pseudomonas aeruginosa is an opportunistic pathogen that
causes both acute and chronic infections in the lungs of
cystic fibrosis (CF) patients, and its presence and the exacer-
bations it causes in CF lungs are generally considered to be
one of the highest mortality risk factors for patients [64]
(but also see [65] for a critical reflection on this dogma).
Between one-third and one-half of CF patients with chronic
P. aeruginosa infections harbour isolates with hypermutator
phenotypes, typically due to mutations that inactivate the
mismatch repair system, most commonly through mutation
of the mutS gene [57,66,67]. By comparing the evolution of
phage resistance in WT PA14 and isogenic DmutS strains,
we find that high mutation rates have a dramatic impact on
the evolution of phage resistance, which changes from
being almost exclusively CRISPR-based in the WT back-
ground to being almost exclusively surface-based in the
DmutS background. These data help us to understand how
natural variation in mutation rates may impact the phylo-
genetic distribution of CRISPR-Cas systems, and have
implications for phage therapy applications, where they
may help to predict the relative importance of CRISPR- and
surface-based resistances on the basis of the bacterial
mutation rate.
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32. Methods
(a) Bacterial and virus strains
Pseudomonas aeruginosa UCBPP-PA14 (referred to as WT, carry-
ing no spacers targeting DMS3vir), P. aeruginosa UCBPP-PA14
csy3::LacZ [63] (also referred to as CRISPR-KO, because it carries
a disruption of an essential cas gene that causes the CRISPR-Cas
system to be non-functional) and P. aeruginosa UCBPP-PA14
mutS::MAR2xT7 [68], which was kindly provided by Alexandro
Rodriguez Rojas (below this strain is also referred to as DmutS or
PA14 mutator strain), and the CRISPR-KO-derived surface mutant
(sm) (described previously here [8]), were used in all experiments.
WT or DmutS bacteriophage-insensitive mutants (BIM) (N ¼ 6)
isolated during the evolution experiment (figure 1), that had
acquired two spacers against phage DMS3vir, were used in the
competition experiment. Cells were grown overnight at 378C in
LB or M9 medium (22 mM Na2HPO4; 22 mM KH2PO4; 8.6 mM
NaCl; 20 mMNH4Cl; 1 mMMgSO4; 0.1 mMCaCl2) supplemented
with 0.2% glucose. The obligately lytic phage DMS3virwas used in
all experiments, and has previously been described in [63].
DMS3vir-acrIF1 was used in downstream analyses and has been
described elsewhere [69]. Phage amplification and titrations were
carried out on P. aeruginosa UCBPP-PA14 csy3::LacZ.
(b) Evolution experiments
To monitor the evolution of bacterial resistance in response to
phage infection and the associated bacterial and phage popu-
lation dynamics, glass vials with 3 ml of LB medium or M9
medium supplemented with 0.2% glucose were inoculated
with approximately 106 bacteria from fresh overnight cultures
of the corresponding bacterial strains. These cultures were
infected with 104 plaque forming units (pfu) of DMS3vir, fol-
lowed by incubation at 378C and shaking at 180 rpm. Cultures
were transferred 1 : 100 into fresh medium every 24 h for 11
days (3 days only for LB). Experiments in M9 were performed
in six independent replicates and those in LB in three independent
replicates.
(c) Measuring bacterial and phage population dynamics
Bacterial densities were determined by plating on LB agar serial
dilutions of samples taken at each transfer in M9 salts (22 mM
Na2HPO4; 22 mM KH2PO4; 8.6 mM NaCl; 20 mM NH4Cl;
1 mM MgSO4; 0.1 mM CaCl2). Phages were extracted at each
transfer by chloroform extraction (sample : chloroform 10 : 1 v/v),
and phage titres were determined by spotting serial dilutions
of isolated phage samples in M9 salts on a lawn of CRISPR-KO
bacteria.
(d) Survival analyses
Phage survival analyses were carried out using GraphPad soft-
ware by plotting the per cent survival phages at each time
(Kaplan–Meier curve). Paired-comparisons of survival curves
were made by applying the Mantel–Cox tests and were con-
sidered statistically significant when p-values were less than a
Bonferroni-corrected threshold of 0.017.
(e) Evolution of resistance
For consistency with previous studies [8,40,69,70], the evolution
of resistance was determined at 3 days post-infection (dpi) by
streaking individual colonies (always 16 randomly picked colo-
nies per replicate) through DMS3vir and DMS3vir-acrIF1.
Surface modification was confirmed by colony morphology,
broad-range resistance to DMS3vir phages carrying
acr genes, and lack of newly acquired spacers. CRISPR-
Cas–mediated immunity was confirmed by PCR using primers50-CTAAGCCTTGTACGAAGTCTC-30 and 50-CGCCGAAGGC-
CAGCGCGCCGGTG-30 for CRISPR array 1, and primers
50-GCCGTCCAGAAGTCACCACCCG-30 and 50-TCAGCAAGT-
TACGAGACCTCG-30 for CRISPR array 2.
( f ) Estimating frequency and rate of surface mutations
in bacterial populations
Six colonies of WT, CRISPR-KO and DmutS strains were picked
and cultured in 6 ml M9 medium overnight. These cultures
were standardized to 0.1 OD600 and diluted 1000-fold. Fifty
microlitres of each culture were used to seed 15 replicate popu-
lations per strain. After 24 h incubation (378C, 180 RPM
shaking), a 200 ml dilution series of each culture was exposed
to 50 ml of either DMS3vir (approx. 1010 PFU ml21, MOI
approx. 500) or buffer and 5 ml immediately spotted on LB
agar plates. The resulting drop plates were counted after 24 h
incubation. The resistance phenotype of surviving colonies was
confirmed by streaking colonies through DMS3vir and
DMS3vir-acrIF1. Mutation rates were estimated from a Luria–
Delbru¨ck model using a maximum-likelihood method
implemented by the FLAN package [71] in R (v. 3.5.1). Signifi-
cance was determined using two-sample fluctuation analysis
tests on mutant counts implemented using the flan.test function
(FLAN [71]).
(g) Competition assays to measure fitness
Competition experiments were performed in glass vials in 6 ml
M9 medium supplemented with 0.2% glucose. Competition
experiments were initiated by inoculating 1 : 100 from a 1 : 1
mixture of overnight cultures (grown in M9 medium þ 0.2%
glucose) of the CRISPR-KO-derived sm strain and either BIM of
the WT or the DmutS strain with two spacers against DMS3vir,
that had been isolated during the evolution experiment. Phage
DMS3vir was added at the start of the experiment at 0, 104, 107
or 109 pfu. Cells were transferred 1 : 100 daily into fresh broth.
At 0, 1, 2 and 3 days, post-infection samples were taken and
cells were serially diluted in M9 salts and plated on LB agar sup-
plemented with 50 mg ml21 X-gal (to allow discrimination
between WT BIM or DmutS BIM bacteria (white) and sm (blue)
bacteria). All experiments were performed in six replicates. Rela-
tive fitness was calculated from changes in the relative
frequencies of blue and white colonies (rel. fitness ¼ [(fraction
strain A at t ¼ x) * (12 (fraction stain A at t ¼ 0))]/[(fraction
strain A at t ¼ 0) * (12 (fraction strain A at t ¼ x)]).3. Results
Clinical isolates of P. aeruginosa commonly have a hypermu-
tator phenotype [57]. To understand if and how this impacts
the benefits of a CRISPR-Cas adaptive immune system, we
performed an evolution experiment and monitored the
bacterial and phage population dynamics as well as the
levels of CRISPR-mediated resistance that evolved following
exposure of either WT PA14, a PA14 CRISPR-KO strain or a
mutator (PA14 DmutS) strain to 104 pfu of phage DMS3vir
[63], a Mu-like phage [72] (figure 1a–j). Pseudomonas
aeruginosa PA14 has a type I–F CRISPR-Cas system [11],
which does not a priori target phage DMS3vir [63]. Consistent
with previous studies [69], we found that following infection
of the WT strain, phage titres rapidly increased, which is
simply because bacteria are initially sensitive to phages and
therefore allow rapid phage amplification. However, from
1 dpi onwards, phage titres started to decline rapidly until
complete extinction at 6 dpi (figure 1a). As expected, bacterial
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Figure 1. DMS3vir viral titre from 0 to 11 dpi of PA14 WT (a), PA14 DmutS (c) or PA14 CRISPR-KO (e) hosts. Bacterial titres during the course of the experiment
were also measured for the same hosts (b), (d ) and (f ), respectively. The average (N ¼ 6) phage (g) and bacterial (h) titres are displayed with error bars that
represent 95% confidence intervals (CI). (i) Survival analysis of phage in different host backgrounds over the course of the experiment. ( j) The immunity profile for
each host at 3 dpi, showing the proportion of bacterial clones that evolved resistance by surface modification (sm) or CRISPR-Cas as well as those that did not evolve
resistance (sensitive). Error bars represent 95% CI.
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5densities remained low during the early stages of the exper-
iment, but recovered from 2 dpi onwards, which coincided
with the rapid decline in phage titres, and presumably
reflects the evolution of phage resistance by the bacteria
(figure 1b). In response to phage infection, P. aeruginosa
strain UCBPP-PA14 can evolve either surface modification
(sm) or CRISPR-Cas–mediated defence [8]. Analysis of indi-
vidual bacterial clones that were isolated at 3 dpi revealed
high levels of phage resistance evolution, and this was
mainly due to CRISPR-mediated immunity of the bacteria
(figure 1j ).
Despite the previously reported benefit of high mutation
rates to the bacteria when exposed to phage infection [60],
when the same experiment was carried out using the PA14
DmutS strain, phage extinction risk was reduced compared
to that observed for the WT strain (figure 1c,g,i, p ¼ 0.005,
Mantel–Cox test), and was similar to that observed following
infection of the CRISPR-KO strain (figure 1e,g,i). Similar to
what was observed for the WT strain, bacterial densities of
the mutator and CRISPR-KO strains were initially low, but
recovered from 2 dpi onwards, despite phage still being pre-
sent (figure 1d ). Interestingly, analysis of individual clones
isolated at 3 dpi revealed that almost all PA14 DmutS bacteria
had evolved surface-based resistance rather than CRISPR-
based immunity (figure 1j ). These findings help to explain
why phage was able to persist for a longer period in the
mutator background, because phages attempting to infect
CRISPR-immune cells are destroyed, leading to a rapid
reduction in their numbers. By contrast, phages cannot
absorb to fully resistant surface-modified hosts and hence
their numbers decrease more gradually through dilution by
serial transfer. Additionally, a lack of phage extinction is
commonly observed following evolution of surface-based
resistance, probably because some surface modification
mutants remain partially sensitive to phage infection [69].
To extend the generality of these findings, we also carried
out this experiment in high nutrient LB media, which favours
the evolution of surface-mediated resistance [8]. As expected,
in these conditions, we found that WT bacteria evolved
low levels of CRISPR-based resistance to DMS3vir, and
mostly evolved resistance by surface modification. The
CRISPR-KO and DmutS populations evolved resistance
exclusively by surface modification in these conditions
(electronic supplementary material, figure S1).
While these data show that high bacterial mutation rates
cause a strong reduction in the evolution of CRISPR resist-
ance, it is unclear why this is the case. We envisaged two
possible explanations (i) the frequency at which surface
mutants are produced is higher in a mutator background
and (ii) CRISPR-resistant clones in a mutator background
are less fit than surface mutants, for example, because
CRISPR immunity is rapidly lost as a consequence of
mutations in the cas genes or CRISPR arrays. The first expla-
nation is intuitively contributing to the observed effects,
because bacterial clones evolve resistance in this system by
random mutation of surface genes, particularly those that
encode the pilus, which acts as the receptor for phage
DMS3vir [8,63]. To formally test this hypothesis, we carried
out a fluctuation test in which replicate populations of WT,
DmutS and the CRISPR-KO were exposed to high phage
titres before plating serial dilutions of the mixtures. By
measuring the plated population size in the absence of
phage and the number of survivors after phage exposure,we were able to calculate the frequency and rate of spon-
taneous surface mutation generation in each host
background (figure 2a,b). The frequency of surface mutants
was higher in the DmutS condition (mean of 7.34  10203
per cell, 95% CI (4.89  10203, 9.80  10203)) compared to
the CRISPR-KO (4.20  10205, 95% CI (1.58  10205, 6.82 
10205)) or WT background (2.37  10204, 95% CI (1.45 
10204, 3.30  10204)) (figure 2a). As the pilus locus is very
large, comprising over 20 genes, the likelihood that it will
acquire mutations is high and many of these will lead to a
‘surface mutant’ phenotype ([73]), which may explain the
relatively high frequencies of phage-resistant surface mutants
we see even in the WT and CRISPR-KO backgrounds.
These data were entered into a modified form of the
Luria–Delbru¨ck mutation rate estimator that implements a
maximum-likelihood method as described by Ycart & Veziris
[74]. The calculated mutation rate of the DmutS strain to a sur-
face mutant phenotype was significantly higher (mean ¼
5.53  10204, s.d. ¼ 1.62  10204) than that of both the WT
(6.71  10205, s.d. ¼ 1.09  10205) and CRISPR-KO (1.17 
10205, s.d. ¼ 2.74  10206) hosts (two-sample ML test t ¼
4.69, p, 0.001, and t ¼ 4.69, p, 0.001, respectively)
(figure 2b). Surprisingly, we also found a small, but signifi-
cant difference in the WT and CRISPR-KO mutation rates
generated by this method (t ¼ 3.9, p, 0.0001). Nonetheless,
this analysis confirmed the prediction that the rate at which
surface mutants are generated is higher (by approx. 10–50
fold) for the mutator background (figure 2b). To test the
second explanation, we competed six independent CRISPR-
resistant clones derived from the WT background or from
the DmutS background against a previously described sur-
face mutant (sm) that carries a lacZ marker gene [8], and
which serves as a reference strain. The evolution of sm
through loss of the phage receptor is frequently reported
to be associated with a fixed fitness cost [8,75,76], whereas
CRISPR-Cas–mediated defence is associated with an induced
fitness cost [8]. Consistent with these previous observations,
these competition experiments demonstrated that the relative
fitness of CRISPR-resistant bacteria depends on the amount
of phage (p  0.0001, F3,40¼ 16.07, by two-way ANOVA), per-
haps due to higher phage numbers leading to CRISPR-Cas
being elicited more frequently and therefore to a higher indu-
cible cost [8], but crucially, it is independent of the mutation
rate of the host (p ¼ 0.51, F1,40¼ 0.44) (figure 2c). Collectively,
these data therefore demonstrate that mutator strains evolve
greater levels of surface resistance because these mutants
pre-exist at higher frequencies in the population, and not
because of a reduced selective advantage of CRISPR-resistant
clones over surface mutants when the host has a higher
mutation rate.4. Discussion
It is commonly acknowledged that CRISPR-Cas adaptive
immune systems frequently move by HGT and provide a
benefit in the face of phage infection, yet they are found in
less than half of the sequenced bacterial genomes. This
apparent paradox may be partly explained by the loss of
CRISPR-Cas systems due to immunopathological effects, i.e.
the cytotoxic effects of self-targeting [25–27]. In addition, the
system may form a barrier for HGT, driving its loss when
HGT is an important fitness determinant [27,35]. Thirdly,
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6other defences may be selected over CRISPR-Cas in some
environments [8,38–40]. Finally, CRISPR-Cas systems may
show negative epistasis with host genes, as was recently
shown to be the case for the NHEJ DNA repair pathway
and type II-A CRISPR-Cas systems [50]. Here, we show that
mutation of the mismatch repair system, which results in a
mutator phenotype, is associated with the virtually undetect-
able evolution of CRISPR-based resistance. We propose that
the benefits of a CRISPR-Cas immune system are reduced in
this genetic background, but this will need to be formally con-
firmed by performing competition experiments between
DmutS strains with and without CRISPR-Cas in the pres-
ence/absence of phages. However, currently, we speculate
that the natural variation in bacterial mutation rates may,
therefore, influence the distribution of these adaptive
immune systems.
Mutator phenotypes frequently arise both in the labora-
tory and in nature, most commonly due to frameshifts,
insertions, premature stop codons or deletions of mutS or
mutL genes [77,78]. These mutators have approximately a
100-fold increased rate of transition from G : C to A : T and
vice versa, a 1000-fold increased rate of frameshift mutations,
as well as a 10- to 1000-fold increase in the rate of chromoso-
mal rearrangements [79]. Despite the increased rate at which
these mutators accumulate deleterious mutations [58,80],they can sometimes outcompete non-mutators, particularly
in fluctuating environments [58,81–86], such as those experi-
enced during the antagonistic coevolution with phages [60].
The selective advantages of mutator phenotypes in fluctuat-
ing stressful environments also help to explain why
mutators are relatively common in nature (sometimes with
frequencies above 60%), and particularly so in pathogens
(including, for example, E. coli, Salmonella enterica, Neisseria
meningitides, Haemophilus influenza, Staphylococcus aureus,
Helicobacter pylori, Streptococcus pneumoniae and P. aeruginosa
(see [79] and references therein). Given that pathogens
occupy niches where they are frequently exposed to various
stressors, mutator phenotypes can provide a selective advan-
tage by accelerating adaptive evolution [55,56,79]. For
example, during colonization of the lungs of CF patients,
P. aeruginosa strains are continuously exposed to osmotic
and oxidative stress, the host immune system and antibiotics
[64], and the observed appearance of mutator phenotypes
during chronic infection may be important in driving rapid
evolution of resistance to these factors [87,88]. This idea is
further supported by the high frequency of mutator strains
in chronically infected CF lungs (20% of isolates and 37%
of patients carrying a mutator in one study [57]) and the posi-
tive relationship between mutator phenotypes and antibiotic
resistance in pathogenic isolates of P. aeruginosa [57].
royalsocietypublishing.org/journal/rstb
Phil.Trans.R.Soc.B
374:20180094
7The relevance of mutator strains in clinical contexts, and
the impact these phenotypes have on the evolution of
phage resistance could be an important consideration in the
context of phage therapy, which is currently undergoing a
revival [89]. Our data show that—at least in an in vitro labora-
tory environment—mutator strains are much less likely to
evolve CRISPR-based resistance and more likely to evolve
surface resistance. Therefore, if the prevalence of mutator
strains in an infection is known, it could be used to predict
the relative importance of different resistance strategies
likely to evolve during treatment. Furthermore, when CF
patients carry mutator strains in their lungs, therapeutic use
of phages may cause rapid emergence of surface mutants
likely to outcompete other resistance strategies in the short
term and become the dominant strain, which could have
knock-on effects for the evolution of virulence and disease
progression. We appreciate that the DmutS mutator strain
chosen for these experiments is likely an extreme example,
with a very high rate of mutations, and that a range of
rates will exist in nature, with some mismatch repair mutants
only having a slightly increased mutation supply rate compared
to WT. This, in turn, may lead to variation in the importance of
CRISPR-Cas in these hosts and further experiments will be
needed to investigate this.
Apart from the biomedical implications, the results pre-
sented here help to shed further light on the factors that
determine whether bacteria evolve surface resistance or
CRISPR-based adaptive immunity against phages. Previous
work with this same model system has shown that natural
selection favours CRISPR-based defences if phage titres arelow, because surface resistance is associated with a fixed
cost of resistance, whereas CRISPR-based immunity is associ-
ated with a cost that is elicited only during phage infections
[8]. Our data show that in addition to selection, the mutation
supply rate also influences the type of phage resistance that
evolves in this system. While we only tested the importance
of mutation rates on the evolution of CRISPR-based versus sur-
face-based resistance under laboratory conditions, if the same
effects to apply in nature, it may, therefore, influence the
benefits and hence the distribution of CRISPR-Cas systems.
Future studies are needed to examine whether such correlations
exist between CRISPR activity and host mutation rates.
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